COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Milestones and Publications

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) brings together leading centers nationwide in a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics, and to address mechanisms of treatment response, resistance, or toxicity. Here are some noteworthy moments in CPTAC history.

CPTAC Timeline and Milestones

Image as of Fall 2019

Selected publications (List as of July 2024)

Multi-scale signaling and tumor evolution in high-grade gliomas Cancer Cell. 2024 Jul 8;42(7):1217-1238.e19. PMID: 38981438
Comprehensive proteogenomic characterization of rare kidney tumors Cell Rep Med. 2024 May 21;5(5):101547. PMID: 38703764
Pan-cancer proteogenomics characterization of tumor immunity Cell. 2024 Feb 29;187(5):1255-1277.e27. PMID: 38359819
Deep learning integrates histopathology and proteogenomics at a pan-cancer level Cell Rep Med. 2023 Sep 19;4(9):101173. PMID: 37582371
Proteogenomic insights suggest druggable pathways in endometrial carcinoma Cancer Cell. 2023 Sep 11;41(9):1586-1605.e15. PMID: 37567170
Pan-cancer proteogenomics connects oncogenic drivers to functional states Cell. 2023 Aug 31; 186 (18): 3921-3944.e25. PMID: 37582357
Proteogenomic data and resources for pan-cancer analysis Cancer Cell. 2023 Aug 14;41(8):1397-1406. PMID: 37582339
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer Cell. 2023 Aug 3;186(16):3476-3498.e35. PMID: 37541199
Proteogenomic characterization of pancreatic ductal adenocarcinoma Cell. 2021 Sep 16;184(19):5031-5052.e26. PMID: 34534465
A proteogenomic portrait of lung squamous cell carcinoma Cell. 2021 Aug 5;184(16):4348-4371.e40. PMID: 34358469
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance Cancer Cell. 2021 Jul 12;39(7):999-1014.e8. PMID: 34171263
Proteogenomic and metabolomic characterization of human glioblastoma Cancer Cell. 2021 Apr 12;39(4):509-528.e20. PMID: 33577785
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy Cell. 2020 Nov 25;183(5):1436-1456.e31. PMID: 33212010
Proteogenomic Characterization of Endometrial Carcinoma. Cell. 2020 Feb 20;180(4):729-748.e26. PMID: 32059776
Microscaled proteogenomic methods for precision oncology Nat Commun. 2020 Jan 27;11(1):532. PMID: 31988290
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma Cell. 2019 Oct 31;179(4):964-983.e31. PMID: 31675502
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities Cell. 2019 May 2;177(4):1035-1049.e19. PMID: 31031003
Proteogenomic Characterization of Human Early-Onset Gastric Cancer Cancer Cell. 2019 Jan 14;35(1):111-124.e10. PMID: 30645970
A proposal for validation of antibodies Nat Methods. 2016 Oct;13(10):823-7. PMID: 27595404
Proteogenomics connects somatic mutations to signalling in breast cancer Nature. 2016 Jun 2;534(7605):55-62. PMID: 27251275
Proteogenomic characterization of human colon and rectal cancer Nature. 2014 Sep 18;513(7518):382-7. PMID: 25043054